Effect of Lamivudine Treatment on Chronic Hepatitis B Infection in Children Unresponsive to Interferon.
- Author:
Gyu Min YEON
1
;
Hye Young KIM
;
Jae Hong PARK
Author Information
1. Department of Pediatrics, School of Medicine, Pusan National University, Busan, Korea. jhongpark@pusan.ac.kr
- Publication Type:Original Article
- Keywords:
Hepatitis B;
Children;
Lamivudine;
Interferon;
Non-responder
- MeSH:
Child;
Hepatitis B;
Hepatitis B e Antigens;
Hepatitis B, Chronic;
Hepatitis, Chronic;
Humans;
Interferons;
Lamivudine;
Male;
Medical Records;
Polymerase Chain Reaction;
Recurrence
- From:Korean Journal of Pediatric Gastroenterology and Nutrition
2008;11(2):137-142
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Interferon is a widely used treatment for chronic hepatitis B in children. However, additional treatment options are needed because more than 50% of hepatitis B patients are unresponsive to interferon. Although lamivudine is widely used to treat hepatitis B, there are few studies on the effect of lamivudine in hepatitis B patients unresponsive to interferon. METHODS: Eight interferon unresponsive patients (6 males and 2 females) were treated with lamivudine (3 mg/kg/day, maximum 100 mg/day) from 6~12 months after interferon treatment was discontinued among 33 children with chronic hepatitis B. They were treated with interferon (interferon alpha-2b, 10 MU/m2 or pegylated interferon 1.5 microgram/kg) for 6 months from January 2000 to December 2007 at the Pusan National University Hospital. The medical records were analyzed retrospectively. RESULTS: The age at treatment with interferon and lamivudine was 4.9+/-3.1 and 6.1+/-3.2 years, respectively. The serum ALT level before treatment with interferon was 148.1+/-105.8 IU/L and the log HBV-DNA PCR mean value was 6.95+/-0.70 copies/mL. The serum ALT level after treatment with interferon was 143.1+/-90.4 IU/L and the log HBV-DNA mean PCR value was 6.46+/-2.08. HBeAg negativization occurred in 2 patients. For all patients, normalization of the serum ALT levels and HBeAg seroconversion (except 2 patients with HBeAg negativization) occurred at 7.4+/-2.1 and 7.9+/-2.1 months respectively after lamivudine treatment. The HBV-DNA PCR became negative in 7 patients (87.5%) at 2.4+/-2.8 months. Complete response was achieved in 7 patients and no recurrence was observed in 2 patients for 3 years after the completion of treatment. Five patients are still under treatment for a mean treatment duration of 24.4+/-9.1 months. In one patient, viral breakthrough occurred and the treatment was stopped. CONCLUSION: The number of patients was small, however, lamivudine treatment in patients with chronic hepatitis B who were unresponsive to interferon was highly effective.
